Abstract: Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. This study aimed to investigate the food effect on the pharmacokinetics (PK) of the recently developed nano-crystallized megestrol acetate (NCMA), using a model-based approach. Data were obtained from an NCMA PK study consisting of a single dose in fasting (39 individuals) and fed conditions (40 individuals). Plasma concentrations were measured up to 120 hr after dosing. With the incorporation of body-weight via allometry, NONMEM 7.3 was used to develop a PK model, which was then used to simulate an optimal fasting dose yielding an area under concentration (AUC) and maximum concentration (C max ) of NCMA close to those obtained with the fed dose. NCMA concentrations were best characterized by a two-compartment model with firstorder absorption linked to a recycling compartment to account for the multiple concentration peaks observed. Food increased bioavailability 2.2 times and decreased the absorption rate constant 0.58 times. Recycling event times were estimated to be 3.56, 7.99 and 24.0 hr. The optimal fast dose was 2.0 times higher than the fed dose, and the resulting difference in drug exposure between the fasting and fed dose was 7.5%. This work suggests that the PK model developed can be applied to an optimal dosage regimen design for NCMA treatment.
Megestrol acetate is a synthetic derivative of progesterone, a natural steroid hormone classified as a BCS class II drug that exhibits low solubility and high permeability [1] . As it was approved by the U.S. Food and Drug Administration (FDA) in 1993 for the treatment of cachexia or anorexia in tablet form, megestrol acetate has been investigated with the aim of overcoming its poor solubility and low oral bioavailability [2, 3] . An oral suspension form was developed and approved by the U.S. FDA in 2001. The oral suspension is a micronized drug formulation, which has been reported to be superior to general solutions in the case of drugs with poor absorption profiles [4] . However, bioavailability remained low. Subsequently, with advancements in pharmaceutical science, nano-crystallized megestrol acetate (NCMA) has been developed. Through animal and human studies, nano-crystallization has been found to enhance bioavailability in a fasting administration to some extent, thereby compensating for reduced systemic exposure compared with that in a fed administration [5] [6] [7] [8] .
Despite these technological improvements in the drug delivery system, oral bioavailability of megestrol acetate is still affected by many factors that may reduce drug absorption. The reason that oral bioavailability should be taken into consideration with megestrol acetate is that a positive relationship between drug exposure and efficacy has been found [3, 5, 9, 10] . One such factor affecting drug absorption is food, which is known to stimulate drug absorption and disposition to varying degrees, depending on the composition of the food. High-fat meals stimulate the bioavailability of megestrol acetate by inhibiting efflux transporters and micelle formation in the intestinal lumen [11, 12] . However, a quantitative analysis of food effect on the overall pharmacokinetic characteristics of megestrol acetate has not previously been performed.
Thus, the goal of this study was to construct a model to identify factors influencing the pharmacokinetic characteristics of megestrol acetate, and then, on the basis of the developed model, to find an optimal preprandial dose that produces concentration profiles similar to those of postprandial drug administration. It is expected that the developed model will be of use in improving the treatment effects of this drug in patients with diseases accompanied by cachexia, including cancer and AIDS.
Materials and Methods
Data. Data were obtained from 79 healthy male volunteers enrolled in a previous pharmacokinetic study to investigate the pharmacokinetics (PK) of a newly developed oral suspension formulation of megestrol acetate (Apetrol ES, LG Life Sciences, Seoul, Korea; NCMA 125 mg per Apetrol ES 1 mL) [13] . The study consisted of two parts, conducted under fasting (Part 1; N = 39) and fed administrations (Part 2; N = 40), where a high-fat diet was provided 30 min. before drug administration in Part 2. In both parts, the volunteers were given a single dose of Apetrol ES 5 mL (NCMA 625 mg) at 8 a.m., followed by standard meals provided at 4 and 10 hr after the dose. Blood samples were collected at 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72, 96 and 120 hr after dosing, where sampling at 7 hr was omitted in Part 2, as it has been reported that T max becomes faster under fed administration. Samples up to 24 hr Author for correspondence: Kyungsoo Park, Department of Pharmacology, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea (fax +82 2 313 1894, e-mail kspark@yuhs.ac).
were obtained, while the volunteers were hospitalized and the rest of the samples were obtained at the outpatient clinic after they were discharged from the hospital.
The study was approved by the Institutional Review Board of Yonsei University Severance Hospital (Seoul, Korea) and performed in accordance with the Declaration of Helsinki and Good Clinical Practice [14] .
Basic structural model. To develop a basic structural model, one-, two-and three-compartment models with zero-or first-order absorption were tested, where lag-time was not considered because absorption delay was not seen in our data. Clearance (CL) and volume of distribution (V) were scaled using allometry, as below [15] , where WT STD is standard body-weight (=70 kg), and CL STD and V STD are the typical clearance and volume of distribution for WT STD , respectively.
Food effect. Food effect was incorporated into the model by allowing a difference in oral bioavailability between the fasting and fed administrations, which was calculated as follows:
Food effect was tested for each model parameter, one by one, in a stepwise manner.
Multiple concentration peaks. One interesting finding observed in our concentration data was a multiple-peak phenomenon, as seen in fig. 1 , which raised the possibility of the existence of recycling mechanisms. To take this into account, several recycling models previously published in other studies were tested [16] [17] [18] . One model tested was one that used the idea of gastric secretion with posterior intestinal reabsorption. In that model, the central compartment is linked to a recycling compartment (REC), which was divided into REC 1 and REC 2 , allowing for two alternating conditions, A and B, using the feature of MTIME in NONMEM; during condition A, REC 1 plays the role of a depot receiving drug from the central compartment and REC 2 delivers the drug back into the system, and in condition B, the roles of REC 1 and REC 2 are reversed. A schematic diagram of this model structure is presented in fig. 2 , and the relevant NONMEM code is found in the Appendix.
In determining the number of MTIMEs in fig. 2 , two-, three-and four-MTIME models were tested, with the number and times of recycling events being assumed to be the same for the two groups given that the same standard meals were provided to both groups at the same scheduled times after dosing. Also, KRA (=the reabsorption rate constant from the recycling compartment to the plasma) was assumed to be not affected by the fasted status and its value was modelled differently from KA (=the absorption rate constant from the depot to the plasma), which was assumed to be affected by food intake.
Covariate analysis. Given the basic model incorporating food and multiple peak-concentration effects, covariate analysis was conducted to test the effects of demographics and laboratory findings such as age, serum creatinine, smoking, drinking status, serum albumin and AST. For the analysis of food and covariate effects, stepwise covariate modelling was used, with the criteria p < 0.01 (DOFV > 6.63, df = 1) for forward selection and p < 0.001 (DOFV > 10.83, df = 1) for backward deletion, where DOFV denotes a difference in NONMEM objective function values (OFVs) between the model with a covariate and the model without a covariate [19] .
Model evaluation. All analyses were performed with NONMEM 7.3.0 (ICON Development Solutions, Hanover, MD, USA) and the firstorder conditional estimation method with INTERACTION. PsN 3.6.2 and R 3.2.0 (http://psn.sourceforge.net) were used for graphical representation of the data [20, 21] .
Model selection was based on OFV, Akaike information criterion (AIC) and precision of parameter estimates. For model evaluation, goodness-of-fit plots of conditional weighted residuals (CWRES) versus population predictions (PRED) and CWRES versus time were examined for the model bias, as well as PRED superimposed on observations (DV) versus time.
A visual predicted check (VPC) was carried out to check for any possible modelling bias as evinced by observed concentrations falling beyond the 95% confidence interval of the 2.5th percentile, median and 97.5th percentile values of model predictions [22] .
Simulation for dose optimization. Given the significant decrease in megestrol concentration in the fasting administration compared with that in the fed administration ( fig. 1 ), a simulation was conducted using the final model to predict an optimal dose to minimize the decrease in megestrol concentration in the fasting administration, relative to that in the fed administration.
In the simulation, the dosing scheme chosen was multiple dosing for 7 days assuming a steady-state, based on the drug elimination half-life of 20-50 hr reported in the literature [6] [7] [8] . The optimal daily dose, D*, to be administered under fasting conditions, was defined as the dose that minimizes the absolute relative error (ERR, %), which is defined as follows: ERR 1 ð%Þ ¼ jAUC ss;fast ðDÞ À AUC ss;fed j AUC fed Â 100 ERR 2 ð%Þ ¼ jC max;ss;fast ðDÞ À C max;ss;fed j C max;ss;fed Â 100
where AUC ss,fast (D) and C max,ss,fast (D) are the typical area under concentration (AUC) and maximum concentration at steady-state, respectively, predicted by the final model with NCMA in mg/day administered at dose D in the fasting state; and AUC ss,fed and C max,ss, fed are the typical AUC and maximum concentration at steady-state, respectively, predicted by the final model with the currently prescribed dose of 625 mg/day administered at fed state, which equal 2.576 9 10 5 ng/mLÁhr and 2999 ng/mL, respectively. Dose optimization was performed with an increment of 62.5 mg, which corresponds to 0.5 mL of the commercially available suspension formulation.
The above dose optimization process was repeated every 10 kg through a body-weight range of 30-100 kg. Table 1 shows volunteer demographic information. Due to the characteristics of healthy volunteers, the demographic distributions were similar between fasting and fed administration groups. The mean age, weight and height were 26.1 yr, 69.1 kg and 175.6 cm for the fasting group, and 26.8 yr, 69.4 kg and 174.5 cm for the fed group, respectively. Figure 1 displays the observed concentration profiles of NCMA under fasting and fed administrations, showing that food intake increased NCMA concentration, yielding a greater than twofold increase.
Results

Data.
Basic structural model.
A two-compartment model with first-order absorption best described the data. Specifically, the OFV values of the oneand two-compartment model were 13,421.28 and 11,766.85, respectively, for zero-order absorption and 13,388.22 and 11,569.42, respectively, for first-order absorption. As for correlations among model parameters, those among CL, V3 and Q significantly improved model fit.
Food effect. Table 2 lists the parameter estimates of the final model characterizing the food effect on the PK of NCMA. For absorption parameters, food increased the typical value of bioavailability, F, 2.2 times when h F = 0.81 was substituted into Eq. (3) (1 versus 0.45) and decreased the absorption rate constant, K a , 0.58 times (0.72 versus 1.24/hr). OFV decreased significantly when the food effect was included in the model (p < 0.001). Systemic clearance, CL and peripheral volume of distribution, V3, were estimated to be 18.1 L/hr and 577.1 L, respectively.
Multiple concentration peaks.
When 2-, 3-and 4-MTIME models were fitted, recycling event times were estimated to be 3.95 and 8.20 hr for 2-MTIME, 3.56, 7.99 and 24.0 hr for 3-MTIME and 3.53, 7.99, 24.0 and 28.0 hr for 4-MTIME model, with resulting OFVs being 11,071.40, 11,009.04 and 11,008.66, respectively, indicating that the 3-MTIME model was the best, in terms of OFV and the number of model parameters. Clearance of the central to the recycled compartment was 6.91 L/ hr, which accounted for 27.6% of the total clearance of the central compartment. The reabsorption rate constant from the recycling compartment to the plasma was estimated to be 4.78 L/hr.
Covariate analysis.
Other than body-weight, which was incorporated into clearance and volume of distribution using allometry, none of the covariates were found to be significant.
Model evaluation. Figure 3 shows goodness-of-fit plots for the final model presented in table 2. As illustrated in the figure, when evaluated by CWRES versus TIME and CWRES versus PRED, no serious misfit was observed. VPC is presented in fig. 4 , which shows that overall 95% prediction intervals of the 2.5th, 50th and 97.5th percentiles all included the observed data well. However, under fasting administration, the model yielded over-predictions at the 97.5th percentile and did not properly follow outlying observations at the 50th percentile near 5 hr after administration under fed administration.
Simulation for dose optimization.
Intermediate values of AUC ss,fed (D), C max,ss,fast (D) and ERR obtained with various test doses during the optimal dose selection procedure are presented in table 3a for the case of a body-weight of 70 kg, and the resulting optimal doses for the range of body-weight tested are presented in table 3b. Table 3a shows that ERR 1 and ERR 2 reached the minimum at 1250 and 1187.5 mg, respectively. As a result, the minimum ERR was obtained as 7.49% at 1250 mg (Apetrol ES 10.0 mL) when ERR 1 and ERR 2 were 10.4% and 4.6%, respectively. Table 3b shows that the optimal dose obtained was 1187.5 mg for body-weight <70 kg and 1250 mg for body-weight over 70 kg. Figure 5 displays the simulated concentration profile for the optimal dose of 1250 mg/day administered in a fasting state, superimposed on that for the usual dose of 625 mg/day administered in the fed state, indicating that, except for the earlier time to C max,ss , the optimal fast dose produced a systemic exposure similar to that of the usual fed dose. Figure 6 displays the predicted NCMA amounts in the two recycling compartments and in the plasma obtained from the same model as used in fig. 5 given a daily dose of 1250 mg for 7 days in the fasting state. The figure shows that concentrations in the recycling compartments also approach steady-state as dosing is repeated.
Discussion
Of the various factors affecting the oral bioavailability of megestrol acetate, this work focused on investigating the food effect on NCMA, which has superior bioavailability compared to conventional formulations when given in a fasting state. This enhanced bioavailability was also observed in our previous pharmacokinetic study [13] , where the C max and AUC last in the fasting administration increased in the nanocrystallized formulation by 5.0 times and 1.5 times, respectively, compared with those of a micronized drug formulation (not shown).
Closely examining the results obtained in this work, table 2 shows that the absorption rate constant in the postprandial condition was much slower than that in the preprandial condition. This might reflect a situation wherein food intake reduces the total surface area available, impeding penetration of the drug through the gut wall [1, 23] . Despite the slower absorption rate due to food intake, bioavailability increased 2.2 times when drug was administered with food. This might be because gastric emptying time delayed by high-fat meal enabled drug molecules to remain longer in the absorption site in the gastrointestinal tract, leading to an increase in bioavailability. , with left panels denoting time ≤120 hr and right panels time ≤24 hr (dots: observations; red line: 2.5%, median and 97.5% percentiles of observations; blue line: 2.5%, median and 97.5% percentiles of predictions; red shaded area: 90% CI of median predictions; blue shaded area: 90% CI of 2.5% and 97.5% of predictions).
In our analysis, the bioavailability of NCMA increased 2.2 times with food intake. This degree of increase was greater than that seen in previous studies that reported 1.1 times to 1.5 times increases with food intake [8, 24] . The higher bioavailability increase in our study might be attributable to various factors, including ethnic differences and the composition of the high-fat meal.
In this work, to capture the multiple peaks in plasma concentration profiles, several models were tested. When MTIMEs were fixed at meal times known a priori [25] based on the assumption that bile secretion triggered by the meal causes the reabsorption of a drug in the system, leading to multiple peaks in the drug plasma concentration profile, the model parameters could not be properly estimated. This may be due to the nature of the data, wherein observed peak times were not centred at a single time-point, but were scattered over a range of times. Other models that estimate the time to release and the release duration of a recycled drug [26] were not implementable as well for the same reason. Consequently, it was concluded that models to estimate the recycling compartment emptying time were not supported by our data. To resolve these difficulties, a model of gastric secretion with posterior intestinal reabsorption was used, which provided a successful estimation result. In this model, as illustrated in fig. 2 , it was assumed that there are two alternate recycling compartments, REC 1 and REC 2 , that the release of drug from the recycling compartment, REC 1 (REC 2 ), to the absorption compartment occurs instantaneously, and that drug is subsequently reabsorbed to the central compartment following KRA, which is defined as the rate-limiting step in reabsorption, and that the drug in the central compartment accumulates in the other recycling compartment, REC 2 (REC 1 ), during that period.
With regard to the results obtained from the final model, the multiple-peak phenomenon might be attributable to enterohepatic recirculation. Among the estimated MTIMEs of 3.56, 7.99 and 24.0 hr, the first 2 MTIMEs were approximately associated with meal times at 4 and 10 hr. The reason that these two MTIMEs were estimated to be somewhat earlier than the meal times might be that the model parameters were estimated by modelling the fasting and fed administration groups together, and thus were likely to be influenced by the fasting group, whose bile secretion could take place before meals. Moreover, a similar discrepancy was also observed in other studies [27, 28] . Therefore, it is reasonable to assert that our model is appropriate for describing enterohepatic recirculation. In addition, the proportion of clearance to the recycling compartment out of total clearance was 27.6% (=6.91/ (18.1 + 6.91)), which is plausible when we consider that excretion to faeces ranges from 7.7% to 30.3% [5, 6] . For the estimate of the last MTIME, one should be cautious in interpretation due to its different nature. As 24-hr sampling was carried out under fasting state at the time when the volunteers were discharged, this recycling event was conjectured to be related to other factors than food, including diurnal variation of steroids, considering that megestrol acetate is a steroidal progestogen. It has been reported that oestrogen, a sex hormone, undergoes enterohepatic recycling, and therefore, it is probable that the derivatives of progesterone, including megestrol acetate, experience the same mechanism of circulation [29] . Thus, the multiple-peak concentration profile of NCMA could be considered a consequence of enterohepatic circulation, and this mechanism might be partly responsible for the improved systemic bioavailability. The last MTIME of 24.0 hr, however, was not clearly seen in the original data shown in fig. 4 . The reason for this can be explained by examining simulated concentrations of the recycling compartments plotted in fig. 6 . It shows that, for t < 12 hr, which corresponds to the early time period after dosing, drug accumulation into the recycling compartment would be rapid due to the rapid concentration change in the plasma, followed by the rapid drug release from the recycling compartment triggered by food intake, leading to two prominent peaks at the MTIMEs of 3.56 and 7.99 hr, whereas for t > 12 hr, corresponding to the late time period after dosing, the slow concentration change in the plasma would result in the slow drug accumulation into the recycling compartment, followed by the slow drug release from the recycling compartment triggered by factors other than food intake (see above), leading to apparently no observable peak near 24 hr.
The drug label of Megace â ES makes no special statements about any difference in safety between preprandial and postprandial doses. The reason that this drug is not prescribed to be taken only before meals, although its systemic exposure is increased by food intake, is likely that adrenal insufficiency related to megestrol acetate has been reported in some patients [30] , and that cachexia patients would have difficulty taking the drug with normal dietary intake. In this regard, based on the linear PK characteristics of Megace â ES [31], the optimal fasting dose to achieve similar drug exposure with respect to C max,ss and AUCs ss as with the fed dose was explored through simulation, in an effort to provide a dosing guideline for cachexia patients to enhance their appetite and restore their nutritional status in a timely fashion, as well as for patients who have eating problems and need dose adjustments for therapeutic efficacy. Moreover, the body-weight-based optimal dosing strategy proposed in this work can be applied to the design of more efficient clinical trials to study dose-effect relationships. 
